Filing Summary
Filing identity: The request metadata identifies Lite Strategy, Inc. and 2011 Q3, but the supplied filing is MEI Pharma, Inc.’s Form 10-Q for the quarter ended March 31, 2013. The summary below reflects the supplied filing. MEI Pharma is a development-stage oncology company; it reports no product revenue.
Business context and reporting period
The filing covers the three and nine months ended March 31, 2013, compared with the same periods in 2012. MEI Pharma’s lead candidate is Pracinostat, acquired from S*BIO in August 2012; its pipeline also includes ME-143 and ME-344. The financial statements are unaudited.
Financial performance and position
| Metric | Three months ended March 31 | Nine months ended March 31 |
|---|---|---|
| R&D expense | 2013: $1.543 million; 2012: $1.490 million | 2013: $4.433 million; 2012: $3.595 million |
| General and administrative expense | 2013: $1.225 million; 2012: $0.811 million | 2013: $3.557 million; 2012: $2.596 million |
| Net loss | 2013: $2.753 million; 2012: $2.269 million | 2013: $7.971 million; 2012: $5.422 million |
| Basic and diluted loss per share | 2013: $0.18; 2012: $0.93 | 2013: $1.00; 2012: $2.70 |
At March 31, 2013, cash and cash equivalents were $24.167 million, total assets $24.947 million, current liabilities $1.782 million, and stockholders’ equity $23.165 million. No debt balance is reported. Operating cash use was $7.278 million for the nine months, versus $5.777 million in 2012; financing provided $25.271 million, primarily from the December 2012 equity financing. Cash increased by $17.965 million from June 30, 2012. The filing reports no revenue or gross margin.
Material changes and notable items
- Nine-month net loss increased by $2.549 million year over year, as R&D and general and administrative expenses rose. Management attributed R&D growth mainly to Pracinostat manufacturing and Phase II preparation and ME-344 Phase I costs; G&A growth included legal, professional, corporate, and share-based compensation costs.
- In December 2012, the company raised $27.5 million in a private placement of common stock and warrants. As of March 31, 2013, warrants remained outstanding for up to 4.596 million shares at $3.12 per share, among other warrant tranches.
- On April 10, 2013, after quarter-end, the company completed an offering of 2.03 million shares at $7.50 per share for $15.225 million in gross proceeds, before discounts and expenses. It planned to use net proceeds for Pracinostat development and general corporate purposes.
- Common shares outstanding were 15.036 million at March 31, 2013; 17,116,571 were reported outstanding as of May 6, 2013. The filing gives effect to a 1-for-6 reverse stock split in its share data.
Outlook, risks, and contingencies
Management expected to initiate a blinded, placebo-controlled Phase II trial of Pracinostat with Vidaza (azacitidine) in patients with MDS in June 2013. It anticipated ongoing operating losses and negative operating cash flows for the foreseeable future and noted that additional financing may eventually be needed; no quantified runway or formal financial guidance is provided.
The S*BIO asset purchase includes potential clinical, regulatory, and sales milestone payments of up to $75.2 million, plus contingent sales-based earn-outs. The CyDex license for Captisol includes a nonrefundable issuance fee, future milestones, and royalties; the company also agreed to source its Captisol requirements from CyDex, subject to termination rights. Clinical and development contracts are generally terminable but may require payment for work and costs incurred. The filing highlights clinical-trial, regulatory, financing, commercialization, competition, manufacturing, and intellectual-property risks. Management reported effective disclosure controls and no material change in internal control over financial reporting during the quarter.
Important facts for investors to verify
- Confirm the issuer and period: the supplied filing is MEI Pharma’s March 31, 2013 Form 10-Q, not a Lite Strategy 2011 Q3 filing.
- Review subsequent clinical and regulatory updates against the stated plan to begin the Pracinostat Phase II MDS trial in June 2013.
- Assess cash burn and the adequacy of available funds for development, including proceeds and costs of the April 2013 offering.
- Evaluate potential dilution from outstanding warrants, options, and the CEO’s 400,000 restricted stock units, as well as milestone and royalty obligations.
- Note the filing’s development-stage status and absence of product revenue; results and financing needs may change materially with clinical progress.